Clinical Utility of Electrical Impedance Spectroscopy
Clinical Utility of Electrical Impedance Spectroscopy
The purpose of this clinical study is to evaluate the clinical utility of the Nevisense in
 normal clinical practice, i.e. the potential effect of implementing Nevisense in clinical
 decision making (Human vs Human & Machine) based on Nevisense measurement at time of biopsy
 decision.
This is a multi-center, prospective, blinded clinical study designed to evaluate clinical
 utility of Nevisense in normal clinical practice, i.e. the potential effect of implementing
 Nevisense in clinical decision making (Human vs Human & Machine) based on Nevisense
 measurement after biopsy decision. The study enrollment will continue until minimum of 180
 subjects are enrolled in the study. Up to 3 US university/hospital investigational sites will
 participate in this study. Biopsying clinician or the investigators from the clinical
 practices of physicians participating in the study will perform the patient and lesion
 assessment for biopsy as standard of care at the clinic.

 Study subjects will be recruited from the clinical practices of physicians participating as
 investigators in this study. Biopsying clinicians provide their assessment to whether s/he
 would have sent the lesion(s) for biopsy had s/he known the EIS information beforehand .
 Thereafter an evaluation of the suspicious lesion with the Nevisense will be performed
 followed by a biopsy of the lesion. The biopsied lesion will be subjected to histological
 analysis.
Inclusion Criteria:

 -  The lesion(s) meet criteria for Nevisense evaluation.

 -  Lesions that present with unclear clinical presentation to allow for clinical
 diagnosis of benign or minimally dysplastic nevus (nevi) -Thus, necessitating a
 biopsy.

 -  Lesions within Nevisense indication for use: Nevisense is indicated for use on
 cutaneous lesions with one or more clinical or historical characteristics of melanoma,
 when a dermatologist chooses to obtain additional information when considering biopsy.
 Nevisense should not be used on clinically obvious melanoma. The Nevisense result is
 one element of the overall clinical assessment. The output of Nevisense should be used
 in combination with clinical and historical signs of melanoma to obtain additional
 information prior to a decision to biopsy. Nevisense is indicated only for use on:

 -  primary skin lesions with a diameter between 2 mm and 20 mm;

 -  lesions that are accessible by the Nevisense probe;

 -  lesions where the skin is intact (i.e. non-ulcerated or non-bleeding lesions);

 -  lesions that do not contain a scar or fibrosis consistent with previous trauma;

 -  lesions not located in areas of psoriasis, eczema, acute sunburn or similar skin
 conditions;

 -  lesions not in hair-covered areas;

 -  lesions which do not contain foreign matter;

 -  lesions not on special anatomic sites (i.e. not for use on acral skin, genitalia,
 eyes, mucosal areas).

 Exclusion Criteria:

 -  Subjects who fail to provide informed consent

 -  Study subjects with underlying medical disease which may alter ability to diagnose
 clinically or inhibit Nevisense from collecting data